The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Baseline C-Reactive Protein Is Associated With Incident Cancer and Survival in Patients With Cancer
Open accessAbstract
Purpose: We tested the hypothesis that baseline plasma levels of C-reactive protein (CRP) are associated with risk of incident cancer in the general population and early death in patients with cancer. Patients and Methods: A total of 10,408 individuals from the Danish general population who had CRP measured at baseline were observed for up to 16 years; 1,624 developed cancer, and of these, 998 patients died during follow-up. Follow-up was 100% complete. We excluded individuals with a cancer diagnosis at baseline. Results: Baseline CRP levels more than 3 versus less than 1 mg/L were associated with multifactorially adjusted hazard ratios of 1.3 (95% CI, 1.0 to 1.6) for cancer of any type, 2.2 (95% CI, 1.0 to 4.6) for lung cancer, 1.9 (95% CI, 0.8 to 4.6) for colorectal cancer, and 0.7 (95% CI, 0.4 to 1.4) for breast cancer. Corresponding hazard ratios for the highest versus the lowest quintile of baseline CRP levels were 1.3 (95% CI, 1.0 to 1.6), 2.1 (95% CI, 1.2 to 3.8), 1.7 (95% CI, 0.8 to 3.2), and 0.9 (95% CI, 0.5 to 1.7), respectively. Multifactorially adjusted hazard ratios for early death in patients with cancer were 1.8 (95% CI, 1.2 to 2.7) for CRP more than 3 versus less than 1 mg/L and 1.4 (95% CI, 1.1 to 1.7) for the highest versus the lowest quintile. Elevated CRP levels were associated with early death in patients with cancer having localized disease, but not in those with metastases (interaction; P = .03). Conclusion: Elevated levels of CRP in cancer-free individuals are associated with increased risk of cancer of any type, of lung cancer, and possibly of colorectal cancer. Moreover, elevated levels of baseline CRP associate with early death after a diagnosis of any cancer, particularly in patients without metastases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
Inflammation and cancer: back to Virchow?
Balkwill, F., & Mantovani, A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04046-0 · Cited by 7,746
C-reactive protein: a critical update
Pepys, M. B., & Hirschfield, G. M. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18921 · Cited by 3,503
C-reactive protein: a critical update
Pepys, M. B., & Hirschfield, G. M. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200318921 · Cited by 3,436
Tietz Textbook of Clinical Chemistry and Molecular Diagnostics
Burtis, E. B. C. A., Ashwood, E. R., & Bruns, D. E. (2011) · Medical Entomology and Zoology · Cited by 2,190
Nordestgaard, B. G., Benn, M., Schnohr, P., & Tybjærg-Hansen, A. (2007) · JAMA · doi:10.1001/jama.298.3.299 · Cited by 2,058
Self-citationClarke, R., Shipley, M., Lewington, S., Youngman, L., Collins, R., Marmot, M., & Peto, R. (1999) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a010013 · Cited by 877
The Danish Cancer Registry--history, content, quality and use.
Storm, H. H., Michelsen, E. V., Clemmensen, I. H., & Pihl, J. (1997) · PubMed · Cited by 790
C-Reactive Protein and the Risk of Incident Colorectal Cancer
Erlinger, T. P. (2004) · JAMA · doi:10.1001/jama.291.5.585 · Cited by 533
Il'yasova, D., Colbert, L. H., Harris, T. B., Newman, A. B., Bauer, D. C., Satterfield, S., & Kritchevsky, S. B. (2005) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-05-0316 · Cited by 479
Cited by
Ridker, P. M., MacFadyen, J. G., Thuren, T., Everett, B. M., Libby, P., Glynn, R. J., Ridker, P., Lorenzatti, A., Krum, H., Varigos, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32247-x · Cited by 1,344
Obesity and Cancer Mechanisms: Tumor Microenvironment and Inflammation
Iyengar, N. M., Gucalp, A., Dannenberg, A. J., & Hudis, C. A. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.4283 · Cited by 1,004
NLRP3 Inflammasome and the IL-1 Pathway in Atherosclerosis
Grebe, A., Hoss, F., & Latz, E. (2018) · Circulation Research · doi:10.1161/circresaha.118.311362 · Cited by 926
Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer
Allin, K. H., & Nordestgaard, B. G. (2011) · Critical Reviews in Clinical Laboratory Sciences · doi:10.3109/10408363.2011.599831 · Cited by 553
Self-citationStudy, A. C., Bojesen, S. E., Study, A. O. C., Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab), (GENICA), G. E. I. A. B. C., (SWE-BRCA), S. B. C. S., The Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON), (EMBRACE), E. S. O. B. &. B. M. C., (GEMO), G. M. O. C. R. I. B. M. C., Pooley, K. A., et al. (2013) · Nature Genetics · doi:10.1038/ng.2566 · Cited by 528
Self-citationElevated C-Reactive Protein Levels, Psychological Distress, and Depression in 73 131 Individuals
Wium-Andersen, M. K., Ørsted, D. D., Nielsen, S. F., & Nordestgaard, B. G. (2013) · JAMA Psychiatry · doi:10.1001/2013.jamapsychiatry.102 · Cited by 489
Self-citationHs-CRP and all-cause, cardiovascular, and cancer mortality risk: A meta-analysis
Li, Y., Zhong, X., Cheng, G., Zhao, C., Zhang, L., Hong, Y., Wan, Q., He, R., & Wang, Z. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.02.003 · Cited by 418
Tumour burden and efficacy of immune-checkpoint inhibitors
Dall’Olio, F. G., Marabelle, A., Caramella, C., Garcia, C., Aldea, M., Chaput, N., Robert, C., & Besse, B. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00564-3 · Cited by 350
Pine, S. R., Mechanic, L. E., Enewold, L., Chaturvedi, A. K., Katki, H. A., Zheng, Y.-L., Bowman, E. D., Engels, E. A., Caporaso, N. E., & Harris, C. C. (2011) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djr216 · Cited by 333
Diagnosis of obesity and use of obesity biomarkers in science and clinical medicine
Nimptsch, K., Konigorski, S., & Pischon, T. (2019) · Metabolism · doi:10.1016/j.metabol.2018.12.006 · Cited by 314
Shrotriya, S., Walsh, D., Bennani-Baiti, N., Thomas, S., & Lorton, C. (2015) · PLOS ONE · doi:10.1371/journal.pone.0143080 · Cited by 274
Postdiagnosis C-Reactive Protein and Breast Cancer Survivorship: Findings from the WHEL Study
Villaseñor, A., Flatt, S. W., Marinac, C., Natarajan, L., Pierce, J. P., & Patterson, R. E. (2014) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-13-0852 · Cited by 89
“The larger report was conducted in a cohort of 2,910 Danish women diagnosed with invasive breast cancer (36).”
BackgroundDaytime napping, sleep duration and serum C reactive protein: a population-based cohort study
Leng, Y., Ahmadi-Abhari, S., Wainwright, N. W. J., Cappuccio, F. P., Surtees, P. G., Luben, R., Brayne, C., & Khaw, K.-T. (2014) · BMJ Open · doi:10.1136/bmjopen-2014-006071 · Cited by 80
“One possible explanation is through a rise in blood pressure or heart rate on awakening from a nap, which might be followed by increased endothelial shear stress and the production of inflammatory mediators.(43) Alternatively, daytime napping could be the consequence of unnoticed nighttime sleep disturb-”
BackgroundHuang, W.-Q., Mo, X.-F., Ye, Y.-B., Shivappa, N., Lin, F.-Y., Huang, J., Hébert, J. R., Yan, B., & Zhang, C.-X. (2017) · British Journal of Nutrition · doi:10.1017/s0007114517001192 · Cited by 47
A review of canakinumab and its therapeutic potential for non-small cell lung cancer
Schenk, K. M., Reuss, J. E., Choquette, K., & Spira, A. I. (2019) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000832 · Cited by 22
Metadata
- Authors
- Allin, K. H., Bojesen, S. E., & Nordestgaard, B. G.
- Venue
- Journal of Clinical Oncology
- Published
- 2009-05-01
- Volume
- 27
- Issue
- 13
- Pages
- 2217-2224
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2131553129
- Cited by
- 419
- References
- 32
- FWCI
- 11.79
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.